Results 41 to 50 of about 54,207 (313)

Phase I dose-escalation and pharmacokinetic study of dasatinib in patients with advanced solid tumors [PDF]

, 2009
PURPOSE: To determine the maximum tolerated dose, dose-limiting toxicity (DLT), and recommended phase II dose of dasatinib in metastatic solid tumors refractory to standard therapies or for which no effective standard therapy exists.
Agarwal, Shruti, Brunton, Valerie G., Demetri, George D., Evans, T.R. Jeffry, Lo Russo, Patricia, MacPherson, Iain R.J., Morgan, Jeffrey A., Paliwal, Prashni, Voi, Maurizio, Wang, Ding   +9 more
core   +1 more source

Dasatinib inhibits actin fiber reorganization and promotes endothelial cell permeability through RhoA‐ROCK pathway

Cancer Medicine, 2017
Treatment with dasatinib, a tyrosine kinase inhibitor, is associated with edema, pleural effusion, and pulmonary edema. We investigated the effect of dasatinib on the barrier function of human microvascular endothelial cells‐1 (HMEC‐1) in vitro and in ...
Swapan K. Dasgupta, Anhquyen Le, K. Vinod Vijayan, Perumal Thiagarajan   +3 more
doaj   +1 more source

Rho-Kinase Inhibition Ameliorates Dasatinib-Induced Endothelial Dysfunction and Pulmonary Hypertension

Frontiers in Physiology, 2018
The multi-kinase inhibitor dasatinib is used for treatment of imatinib-resistant chronic myeloid leukemia, but is prone to induce microvascular dysfunction.
Csilla Fazakas, Csilla Fazakas, Chandran Nagaraj, Diana Zabini, Attila G. Végh, Leigh M. Marsh, Imola Wilhelm, István A. Krizbai, Horst Olschewski, Andrea Olschewski, Zoltán Bálint, Zoltán Bálint   +11 more
doaj   +1 more source

Retracted: Dasatinib promotes TRAIL‐mediated apoptosis by upregulating CHOP‐dependent death receptor 5 in gastric cancer

FEBS Open Bio, 2018
Dasatinib, a tyrosine kinase inhibitor, has been approved for first‐line treatment of leukemia and has also been evaluated for use in numerous other cancers. However, its role in gastric cancer (GC) remains unclear.
Xiaona Wang, Qiang Xue, Liangliang Wu, Baogui Wang, Han Liang   +4 more
doaj   +1 more source

MEK/ERK dependent activation of STAT1 mediates dasatinib-induced differentiation of acute myeloid leukemia. [PDF]

PLoS ONE, 2013
Dasatinib (BMS-354825) is a FDA-approved multitargeted kinase inhibitor of BCR/ABL and Src kinases. It is now used in the treatment of chronic myelogenous leukemia (CML) with resistance or intolerance to prior therapies, including imatinib.
Yanfen Fang, Like Zhong, Meihua Lin, Xinglu Zhou, Hui Jing, Meidan Ying, Peihua Luo, Bo Yang, Qiaojun He   +8 more
doaj   +1 more source

Dendritic cell vaccines targeting tumor blood vessel antigens in combination with dasatinib induce therapeutic immune responses in patients with checkpoint-refractory advanced melanoma

Journal for ImmunoTherapy of Cancer, 2021
Background A first-in-human, randomized pilot phase II clinical trial combining vaccines targeting overexpressed, non-mutated tumor blood vessel antigens (TBVA) and tyrosine kinase inhibitor dasatinib was conducted in human leukocyte antigen (HLA)-A2 ...
W. Storkus, Deena M. Maurer, Yan Lin, Fei Ding, A. Bose, D. Lowe, Amy Rose, M. Demark, L. Karapetyan, Jennifer L. Taylor, M. Chelvanambi, Ronald J Fecek, J. Filderman, T. Looney, L. Miller, E. Linch, G. Lowman, P. Kalinski, L. Butterfield, A. Tarhini, H. Tawbi, J. Kirkwood   +21 more
semanticscholar   +1 more source

The shady side of dasatinib [PDF]

Blood, 2012
In this issue of Blood , Futosi and colleagues investigate the effects of the multikinase inhibitor dasatinib on mature human neutrophils, helping to explain the increased infection rate in chronic myelogenous leukemia (CML) patients resistant to or intolerant of imatinib.
openaire   +3 more sources

Dasatinib-Induced Pleural and Pericardial Effusions [PDF]

Cureus, 2021
Chronic myeloid leukemia (CML) is a myeloproliferative disease associated with the Philadelphia chromosome and BCR-ABL1 fusion gene. Tyrosine kinase inhibitors (TKI) are now the standard therapy for this condition. Among the approved TKIs for CML is dasatinib.
Ahmed Elyas, Yousef Hailan, Mohamed A. Yassin, Mohammad Abdul-Jaber Abdulla   +3 more
openaire   +3 more sources

Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival [PDF]

, 2012
Recent evidence suggests CML stem cells are insensitive to kinase inhibitors and responsible for minimal residual disease in treated patients. We investigated whether CML stem cells, in a transgenic mouse model of CML-like disease or derived from ...
Anderson, Ashley Hamilton, Bhatia, Bin Zhang, Branford, Carsten Müller-Tidow, Chen, Chomel, Chu, Copland, Corbin, Daley, Druker, Druker, Druker, Elaine K. Allan, Felsher, Franck E. Nicolini, G. Vignir Helgason, Gabert, Gorre, Gothert, Graham, Hamilton, Hayette, Holyoake, Hughes, Hurtz, Jiang, Jordan, Jordanides, Jorgensen, Konig, Konig, Konig, Koschmieder, Li, Lombardo, Lugo, Mirle Schemionek, Myssina, Notta, Pellicano, Ravi Bhatia, Samanta, Samanta, Schemionek, Scott, Shachaf, Shah, Sharma, Sharma, Sobrinho-Simoes, Steffen Koschmieder, Svetlana Myssina, Talpaz, Tessa L. Holyoake, Valerie G. Brunton, Wang, Weinstein, Weisberg, White   +61 more
core   +1 more source

Treatment Effects of the Second-Generation Tyrosine Kinase Inhibitor Dasatinib on Autoimmune Arthritis

Frontiers in Immunology, 2019
Rheumatoid arthritis (RA) is a multifactorial autoimmune disease that primarily manifests as persistent synovitis and progressive joint destruction.
Kai Guo, Kai Guo, Xin Bu, Chongfei Yang, Xiaorui Cao, Huan Bian, Qingsheng Zhu, Jinyu Zhu, Dawei Zhang   +8 more
doaj   +1 more source